A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

Study acronym: SURPASS-EARLY
StatusActive, Not Recruiting
PhasePhase 4
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Oct 2025 to Oct 21, 2025v37
  2. 3 versions Re-verified since Jan 22, 2025, no change to tracked fieldsv34-v36
  3. Primary completion date: Oct 30, 2025 to Oct 2025
    • Study completion date: Nov 29, 2027 to Nov 2027
    v33
  4. Study sites revised (90)v32
  5. Study sites revised (90)v31
Show 29 earlier versionsHide 29 earlier versions
  1. Study sites: 89 to 90v30
  2. Study sites: 90 to 89v29
  3. Study sites: 86 to 90v28
  4. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 86 of 86 sites
    v27
  5. Site details revised at 6 of 86 sitesv26
  6. Study sites: 89 to 86v25
  7. Study sites: 98 to 89
    • Primary completion date: Aug 27, 2025 to Oct 30, 2025
    • Study completion date: Sep 22, 2027 to Nov 29, 2027
    v24
  8. Primary completion date: Jul 9, 2025 to Aug 27, 2025
    • Study completion date: Jun 7, 2027 to Sep 22, 2027
    • Site contacts updated at 8 of 98 sites
    v23
  9. Site details revised at 7 of 98 sitesv22
  10. Site contacts updated at 3 of 98 sitesv21
  11. Site contacts updated at 3 of 98 sitesv20
  12. Site contacts updated at 1 of 98 sitesv19
  13. Study sites: 97 to 98
    • Primary completion date: May 9, 2025 to Jul 9, 2025
    v18
  14. Site contacts updated at 3 of 97 sitesv17
  15. Study sites revised (97)v16
  16. Study sites revised (97)v15
  17. Study sites revised (97)v14
  18. Study sites revised (97)v13
  19. Study sites revised (97)v12
  20. Site details revised at 15 of 97 sitesv11
  21. Site details revised at 11 of 97 sitesv10
  22. Site details revised at 10 of 97 sitesv9
  23. Study sites revised (97)v8
  24. Site details revised at 9 of 97 sitesv7
  25. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Mar 31, 2025 to May 9, 2025
    • Study completion date: May 10, 2027 to Jun 7, 2027
    • Site details revised at 97 of 97 sites
    v6
  26. Study sites: 98 to 97v5
  27. Site details revised at 7 of 98 sitesv4
  28. Site details revised at 1 of 98 sitesv3
  29. Study sites: 97 to 98v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Eli Lilly
366 trials monitored
See 16 trials at risk
Diabetes
5,141 trials monitored
See 246 trials at risk
Type 2 Diabetes
2,257 trials monitored
See 120 trials at risk
This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.
Trial Details
NCT Number NCT05433584
Lead Sponsor Eli Lilly and Company
Conditions
(from sponsor)		 Type 2 Diabetes
Related terms Diabetes Mellitus, Diabetes Mellitus, Type 2
Enrollment 780 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov